Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VR506
- Development stage
- Phase 3
- Lead developer
- Phillips-Medisize
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
VR506 is an inhaled corticosteroid small molecule drug developed for the treatment of asthma. It was designed as a monotherapy for persistent and severe asthma, delivered via Vectura’s proprietary dry powder inhaler technology. The mechanism of action is as a glucocorticoid receptor agonist, targeting the glucocorticoid receptor (GR) to reduce inflammation in the airways. Clinical trials reached up to Phase 3 before development was discontinued. The drug was originally developed by Vectura Group and intended for licensing and commercialization in partnership with an undisclosed US company[1][4][5].
- Other names
- fluticasone propionate
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on VR506.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VR506.